LUZERN

MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIRAPARIB PLUS AROMATASE INHIBITORS FOR HORMONE RECEPTOR (HR)-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE METASTATIC BREAST CANCERS WITH EITHER GERMLINE BRCA-MUTATED OR GERMINAL BRCA-WILD-TYPE AND HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) – THE LUZERN STRATEGY. THE PRIMARY GOAL IS TO ASSESS THE EFFICACY –AS DETERMINED BY THE CLINICAL BENEFIT RATE (CBR)– OF NIRAPARIB IN COMBINATION WITH AIS IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-POSITIVE/HER2-NEGATIVE BREAST CANCER PATIENTS HARBORING EITHER GBRCAMS OR GBRCAWT AND HRD.